Frederick St Goar, MD
Cardiovascular Disease (Cardiology) · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 20
- 6 carriers
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
20 plans · 6 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Goar’s office at (650) 962-4690 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
20 of 20 plans
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G57372 · Current
Licensed to practise in California · since 1986 · expires 2028-01-31 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$23,443
Medicare paid this office $23,443 for 126 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 116 | $18,208 | $76 |
| Short return visit | 19 | $1,282 | $49 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 50 | $663 | $12 |
Who their Medicare patients are
126 Original Medicare patients in 2024. Average age 81 · Under 65 0% · 85 and older 37% · Women 34% · Health risk score 1.10. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 65% · Atrial fibrillation 34% · Chronic kidney disease 32% · Diabetes 30% · Heart failure 21% · Cancer 21% · Stroke 11% · COPD 10%.
The office billed $102,071, Medicare allowed $33,982 and paid $23,443; for 391 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 126 | 391 | 81 | 1.10 | $102,071 | $23,443 |
| 2023 | 130 | 482 | 81 | 1.21 | $98,152 | $30,047 |
| 2022 | 157 | 574 | 81 | 1.11 | $101,750 | $37,130 |
| 2021 | 438 | 1,016 | 79 | 1.73 | $119,211 | $46,685 |
| 2020 | 454 | 902 | 80 | 1.90 | $103,313 | $35,504 |
| 2019 | 553 | 1,187 | 80 | 1.96 | $147,643 | $49,542 |
| 2018 | 552 | 1,213 | 79 | 1.73 | $163,100 | $53,994 |
| 2017 | 588 | 1,323 | 80 | 1.74 | $184,502 | $64,712 |
| 2016 | 465 | 1,428 | 81 | 1.54 | $233,600 | $79,563 |
| 2015 | 641 | 1,743 | 81 | 1.66 | $300,143 | $84,051 |
| 2014 | 499 | 1,696 | 82 | 1.46 | $339,383 | $95,970 |
| 2013 | 676 | 1,876 | 81 | 1.63 | $428,503 | $107,637 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Short return visit (20+ min) | 119 | $19,667 | $76 |
| Telephone medical discussion with physician, 21-30 minutes | 21 | $2,200 | $67 |
| Return visit (30+ min) | 12 | $1,590 | $114 |
| Telephone medical discussion with physician, 11-20 minutes | 16 | $1,004 | $48 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 60 | $765 | $12 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $337 | $19 |
2022: 6 services
| Short return visit (20+ min) | 145 | $25,842 | $75 |
| Telephone medical discussion with physician, 11-20 minutes | 37 | $4,492 | $69 |
| Return visit (30+ min) | 17 | $1,662 | $92 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $1,244 | $96 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 56 | $793 | $13 |
| Programming of dual lead pacemaker system | 11 | $564 | $33 |
2021: 6 services
| Short return visit (20+ min) | 151 | $34,393 | $78 |
| Return visit (30+ min) | 20 | $4,367 | $121 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 281 | $2,717 | $7 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 65 | $902 | $13 |
| Short return visit | 11 | $751 | $50 |
| Programming of dual lead pacemaker system | 11 | $608 | $32 |
2020: 6 services
| Short return visit (20+ min) | 163 | $25,166 | $65 |
| Return visit (30+ min) | 26 | $3,133 | $95 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 285 | $2,745 | $8 |
| Short return visit | 23 | $1,201 | $44 |
| Programming of dual lead pacemaker system | 12 | $614 | $32 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 30 | $370 | $11 |
2019: 6 services
| Short return visit (20+ min) | 201 | $26,568 | $64 |
| Return visit (30+ min) | 98 | $12,056 | $86 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 330 | $3,000 | $8 |
| Programming of dual lead pacemaker system | 21 | $2,543 | $61 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 89 | $1,356 | $14 |
| Blood test, clotting time | 11 | $124 | $4 |
2018: 7 services
| Return visit (30+ min) | 151 | $22,140 | $89 |
| Short return visit (20+ min) | 201 | $21,208 | $60 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 305 | $2,655 | $7 |
| Programming of dual lead pacemaker system | 22 | $1,891 | $47 |
| Long return visit (40+ min) | 11 | $1,456 | $121 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 69 | $1,038 | $14 |
| Blood test, clotting time | 11 | $124 | $5 |
2017: 7 services
| Return visit (30+ min) | 181 | $32,636 | $92 |
| Short return visit (20+ min) | 200 | $19,682 | $61 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 316 | $2,822 | $7 |
| Programming of dual lead pacemaker system | 19 | $1,764 | $53 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 91 | $1,338 | $14 |
| Programming of single lead pacemaker system | 11 | $973 | $46 |
| Blood test, clotting time | 13 | $180 | $5 |
2016: 8 services
| Return visit (30+ min) | 199 | $35,631 | $91 |
| Short return visit (20+ min) | 263 | $25,849 | $55 |
| Programming of dual lead pacemaker system | 31 | $2,514 | $47 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 166 | $2,452 | $14 |
| New patient visit (30+ min) | 23 | $1,776 | $77 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,764 | $63 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 115 | $1,055 | $7 |
| Blood test, clotting time | 22 | $247 | $5 |
2015: 7 services
| Short return visit (20+ min) | 289 | $34,140 | $59 |
| Return visit (30+ min) | 173 | $29,227 | $89 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 235 | $3,380 | $13 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 294 | $2,854 | $7 |
| New patient visit (30+ min) | 19 | $1,596 | $84 |
| Programming of dual lead pacemaker system | 22 | $1,272 | $51 |
| Blood test, clotting time | 24 | $299 | $5 |
2014: 12 services
| Short return visit (20+ min) | 324 | $41,028 | $60 |
| Return visit (30+ min) | 158 | $24,382 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $3,429 | $62 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 222 | $3,315 | $14 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,058 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $1,941 | $92 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 73 | $1,852 | $18 |
| New patient visit (30+ min) | 20 | $1,608 | $80 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 26 | $1,493 | $57 |
| Blood test, clotting time | 95 | $847 | $5 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $798 | $33 |
| Hospital discharge day management, 30 minutes or less | 11 | $720 | $65 |
2013: 9 services
| Short return visit (20+ min) | 316 | $39,288 | $62 |
| Return visit (30+ min) | 217 | $37,819 | $89 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 187 | $3,184 | $16 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $2,922 | $62 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 13 | $2,908 | $208 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 255 | $2,227 | $7 |
| New patient visit (30+ min) | 14 | $1,289 | $92 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 19 | $1,155 | $55 |
| Blood test, clotting time | 40 | $400 | $5 |
Medicaid work
$614 in 2021
Medicaid paid $614 for 156 billed services this clinician did in 2021, up to 69 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 156 | $614 |
| 2021 | 156 | 1 | 69 | $614 |
| 2020 | 146 | 1 | 68 | $719 |
| 2019 | 133 | 1 | 66 | $686 |
| 2018 | 87 | 1 | 33 | $410 |
See the largest Medicaid services in earlier years
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 146 | $719 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 133 | $686 |
2018
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 87 | $410 |
Drugs they prescribed that Part D paid
$100,087
Pharmacies billed $100,087 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 646) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
564 generic and 82 brand-name prescriptions · $100,087 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 27 | $37,922 | $1,405 |
| Repatha Sureclick | 11 | $13,547 | $1,232 |
| Rosuvastatin | 78 | $1,063 | $14 |
| Atorvastatin | 65 | $1,019 | $16 |
| Ezetimibe | 23 | $874 | $38 |
See all 15 drugs
| Eliquis | 27 | $37,922 | $1,405 |
| Repatha Sureclick | 11 | $13,547 | $1,232 |
| Rosuvastatin | 78 | $1,063 | $14 |
| Atorvastatin | 65 | $1,019 | $16 |
| Ezetimibe | 23 | $874 | $38 |
| Metoprolol | 38 | $678 | $18 |
| Losartan | 36 | $575 | $16 |
| Potassium Chloride | 25 | $461 | $18 |
| Nitroglycerin | 26 | $387 | $15 |
| Clopidogrel | 21 | $273 | $13 |
| Furosemide | 31 | $241 | $8 |
| Metoprolol | 24 | $213 | $9 |
| Carvedilol | 18 | $133 | $7 |
| Amlodipine Besylate | 19 | $56 | $3 |
| Hydrochlorothiazide | 12 | $26 | $2 |
Year by year
| 2024 | 646 | 96 | 0% (0) | 13% | $100,087 |
| 2023 | 750 | 95 | 0% (0) | None | $124,389 |
| 2022 | 798 | 110 | 0% (0) | 11% | $111,860 |
| 2021 | 789 | 115 | 0% (0) | 12% | $83,157 |
| 2020 | 967 | 133 | 0% (0) | 13% | $102,658 |
| 2019 | 1,183 | 154 | 0% (0) | 11% | $98,102 |
| 2018 | 1,438 | 165 | None | 13% | $95,828 |
| 2017 | 1,557 | 177 | None | 14% | $98,051 |
| 2016 | 1,816 | 202 | None | 22% | $143,781 |
| 2015 | 2,021 | 209 | None | 23% | $140,159 |
| 2014 | 2,189 | 215 | 0% (0) | None | $130,363 |
| 2013 | 2,207 | 197 | 0% (0) | 28% | $137,709 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Eliquis | 41 | $51,912 | $1,266 |
| Entresto | 13 | $24,267 | $1,867 |
| Rosuvastatin | 87 | $1,696 | $19 |
| Metoprolol | 59 | $1,136 | $19 |
| Atorvastatin | 71 | $951 | $13 |
| Clopidogrel | 31 | $730 | $24 |
| Ezetimibe | 15 | $631 | $42 |
| Potassium Chloride | 20 | $615 | $31 |
| Losartan | 42 | $607 | $14 |
| Carvedilol | 34 | $445 | $13 |
| Isosorbide Mononitrate Er | 12 | $309 | $26 |
| Nitroglycerin | 19 | $269 | $14 |
| Spironolactone | 12 | $224 | $19 |
| Furosemide | 19 | $167 | $9 |
| Amlodipine Besylate | 27 | $165 | $6 |
| Metoprolol | 22 | $110 | $5 |
| Hydrochlorothiazide | 19 | $47 | $2 |
2022: 20 drugs
| Eliquis | 47 | $60,496 | $1,287 |
| Rosuvastatin | 80 | $2,124 | $27 |
| Ezetimibe | 14 | $1,998 | $143 |
| Metoprolol | 68 | $1,318 | $19 |
| Atorvastatin | 69 | $909 | $13 |
| Valsartan-Hydrochlorothiazide | 11 | $837 | $76 |
| Clopidogrel | 32 | $726 | $23 |
| Carvedilol | 38 | $651 | $17 |
| Potassium Chloride | 25 | $628 | $25 |
| Nitroglycerin | 23 | $603 | $26 |
| Valsartan | 12 | $406 | $34 |
| Isosorbide Mononitrate Er | 12 | $370 | $31 |
| Furosemide | 35 | $332 | $9 |
| Simvastatin | 23 | $318 | $14 |
| Losartan | 26 | $265 | $10 |
| Metoprolol | 28 | $217 | $8 |
| Clonidine | 11 | $216 | $20 |
| Spironolactone | 18 | $175 | $10 |
| Amlodipine Besylate | 26 | $146 | $6 |
| Hydrochlorothiazide | 11 | $44 | $4 |
2021: 22 drugs
| Eliquis | 39 | $46,839 | $1,201 |
| Rosuvastatin | 80 | $3,786 | $47 |
| Metoprolol | 61 | $1,502 | $25 |
| Valsartan-Hydrochlorothiazide | 13 | $1,233 | $95 |
| Atorvastatin | 71 | $1,136 | $16 |
| Valsartan | 15 | $918 | $61 |
| Isosorbide Mononitrate Er | 24 | $868 | $36 |
| Ezetimibe | 11 | $695 | $63 |
| Carvedilol | 37 | $618 | $17 |
| Potassium Chloride | 23 | $518 | $23 |
| Clopidogrel | 23 | $439 | $19 |
| Simvastatin | 29 | $418 | $14 |
| Nitroglycerin | 20 | $313 | $16 |
| Warfarin | 11 | $307 | $28 |
| Metoprolol | 31 | $306 | $10 |
| Atenolol | 12 | $304 | $25 |
| Amlodipine Besylate | 48 | $290 | $6 |
| Furosemide | 34 | $265 | $8 |
| Losartan-Hydrochlorothiazide | 13 | $234 | $18 |
| Spironolactone | 12 | $190 | $16 |
| Lisinopril | 12 | $156 | $13 |
| Losartan | 11 | $64 | $6 |
2020: 28 drugs
| Eliquis | 45 | $49,163 | $1,093 |
| Xarelto | 12 | $14,785 | $1,232 |
| Praluent | 11 | $11,011 | $1,001 |
| Rosuvastatin | 68 | $3,656 | $54 |
| Metoprolol | 86 | $3,269 | $38 |
| Atorvastatin | 110 | $2,357 | $21 |
| Valsartan-Hydrochlorothiazide | 16 | $1,861 | $116 |
| Losartan-Hydrochlorothiazide | 16 | $1,130 | $71 |
| Isosorbide Mononitrate Er | 30 | $1,044 | $35 |
| Nifedipine Er | 15 | $962 | $64 |
| Simvastatin | 49 | $677 | $14 |
| Potassium Chloride | 20 | $656 | $33 |
| Diltiazem 24hr Er (Cd) | 12 | $651 | $54 |
| Clopidogrel | 38 | $645 | $17 |
| Dilt-Xr | 12 | $466 | $39 |
| Atenolol | 25 | $446 | $18 |
| Carvedilol | 38 | $424 | $11 |
| Olmesartan Medoxomil | 12 | $403 | $34 |
| Amlodipine Besylate | 48 | $395 | $8 |
| Warfarin | 19 | $394 | $21 |
| Furosemide | 35 | $341 | $10 |
| Metoprolol | 35 | $316 | $9 |
| Lisinopril | 27 | $300 | $11 |
| Nitroglycerin | 14 | $289 | $21 |
| Triamterene-Hydrochlorothiazid | 11 | $256 | $23 |
| Losartan | 18 | $254 | $14 |
| Spironolactone | 12 | $182 | $15 |
| Hydrochlorothiazide | 12 | $69 | $6 |
2019: 29 drugs
| Eliquis | 31 | $26,954 | $869 |
| Xarelto | 14 | $17,413 | $1,244 |
| Metoprolol | 104 | $3,963 | $38 |
| Rosuvastatin | 70 | $3,839 | $55 |
| Atorvastatin | 118 | $3,098 | $26 |
| Clopidogrel | 64 | $1,629 | $25 |
| Nifedipine Er | 16 | $1,529 | $96 |
| Potassium Chloride | 30 | $964 | $32 |
| Simvastatin | 57 | $734 | $13 |
| Diltiazem 24hr Er (Cd) | 14 | $730 | $52 |
| Metoprolol | 47 | $716 | $15 |
| Isosorbide Mononitrate Er | 17 | $715 | $42 |
| Digoxin | 11 | $701 | $64 |
| Nitroglycerin | 27 | $657 | $24 |
| Amlodipine Besylate | 57 | $649 | $11 |
| Dilt-Xr | 14 | $504 | $36 |
| Furosemide | 56 | $501 | $9 |
| Warfarin | 36 | $491 | $14 |
| Valsartan-Hydrochlorothiazide | 12 | $474 | $39 |
| Ramipril | 13 | $423 | $33 |
| Atenolol | 23 | $406 | $18 |
| Carvedilol | 46 | $405 | $9 |
| Lisinopril | 46 | $386 | $8 |
| Clonidine | 13 | $281 | $22 |
| Losartan | 22 | $274 | $12 |
| Losartan-Hydrochlorothiazide | 14 | $211 | $15 |
| Tamsulosin | 11 | $187 | $17 |
| Spironolactone | 12 | $145 | $12 |
| Hydrochlorothiazide | 21 | $128 | $6 |
2018: 31 drugs
| Xarelto | 16 | $19,198 | $1,200 |
| Eliquis | 25 | $15,648 | $626 |
| Rosuvastatin | 87 | $4,801 | $55 |
| Metoprolol | 121 | $3,966 | $33 |
| Atorvastatin | 138 | $3,573 | $26 |
| Potassium Chloride | 54 | $1,938 | $36 |
| Nifedipine Er | 30 | $1,398 | $47 |
| Clopidogrel | 61 | $1,259 | $21 |
| Isosorbide Mononitrate Er | 28 | $1,235 | $44 |
| Ezetimibe | 15 | $1,185 | $79 |
| Nitroglycerin | 29 | $862 | $30 |
| Diltiazem 24hr Er (Cd) | 25 | $765 | $31 |
| Dilt-Xr | 11 | $729 | $66 |
| Warfarin | 40 | $689 | $17 |
| Simvastatin | 66 | $617 | $9 |
| Metoprolol | 61 | $581 | $10 |
| Lisinopril | 41 | $566 | $14 |
| Carvedilol | 48 | $527 | $11 |
| Amlodipine Besylate | 67 | $526 | $8 |
| Furosemide | 72 | $471 | $7 |
| Isosorbide Mononitrate | 14 | $447 | $32 |
| Valsartan-Hydrochlorothiazide | 13 | $433 | $33 |
| Ramipril | 22 | $418 | $19 |
| Atenolol | 30 | $385 | $13 |
| Valsartan | 12 | $358 | $30 |
| Triamterene-Hydrochlorothiazid | 19 | $297 | $16 |
| Losartan | 20 | $223 | $11 |
| Digitek | 11 | $180 | $16 |
| Spironolactone | 18 | $173 | $10 |
| Lisinopril-Hydrochlorothiazide | 13 | $126 | $10 |
| Hydrochlorothiazide | 16 | $76 | $5 |
2017: 32 drugs
| Xarelto | 18 | $16,130 | $896 |
| Rosuvastatin | 69 | $4,874 | $71 |
| Metoprolol | 118 | $4,707 | $40 |
| Atorvastatin | 156 | $3,669 | $24 |
| Ezetimibe | 19 | $2,573 | $135 |
| Potassium Chloride | 47 | $2,029 | $43 |
| Valsartan | 24 | $1,845 | $77 |
| Nifedipine Er | 30 | $1,472 | $49 |
| Isosorbide Mononitrate Er | 45 | $1,437 | $32 |
| Digoxin | 27 | $1,229 | $46 |
| Clopidogrel | 60 | $1,098 | $18 |
| Isosorbide Mononitrate | 32 | $1,080 | $34 |
| Amlodipine Besylate | 65 | $833 | $13 |
| Nitroglycerin | 26 | $812 | $31 |
| Warfarin | 53 | $788 | $15 |
| Valsartan-Hydrochlorothiazide | 20 | $781 | $39 |
| Diltiazem 24hr Er | 33 | $776 | $24 |
| Metoprolol | 74 | $627 | $8 |
| Simvastatin | 68 | $597 | $9 |
| Furosemide | 65 | $580 | $9 |
| Carvedilol | 44 | $518 | $12 |
| Lisinopril | 46 | $508 | $11 |
| Triamterene-Hydrochlorothiazid | 20 | $425 | $21 |
| Atenolol | 38 | $301 | $8 |
| Ramipril | 14 | $286 | $20 |
| Clonidine | 23 | $253 | $11 |
| Losartan | 19 | $233 | $12 |
| Lisinopril-Hydrochlorothiazide | 24 | $206 | $9 |
| Hydralazine | 11 | $151 | $14 |
| Pantoprazole | 11 | $134 | $12 |
| Spironolactone | 14 | $107 | $8 |
| Hydrochlorothiazide | 21 | $103 | $5 |
2016: 38 drugs
| Crestor | 44 | $24,942 | $567 |
| Xarelto | 20 | $15,602 | $780 |
| Zetia | 46 | $14,245 | $310 |
| Vytorin | 26 | $11,924 | $459 |
| Multaq | 12 | $6,668 | $556 |
| Metoprolol | 133 | $5,179 | $39 |
| Rosuvastatin | 27 | $4,608 | $171 |
| Atorvastatin | 161 | $4,076 | $25 |
| Valsartan | 28 | $2,528 | $90 |
| Potassium Chloride | 47 | $2,332 | $50 |
| Isosorbide Mononitrate Er | 54 | $2,126 | $39 |
| Nifedipine Er | 39 | $1,883 | $48 |
| Clopidogrel | 64 | $1,680 | $26 |
| Nitrostat | 42 | $1,503 | $36 |
| Digoxin | 21 | $1,219 | $58 |
| Warfarin | 65 | $1,077 | $17 |
| Amlodipine Besylate | 76 | $1,039 | $14 |
| Metoprolol | 107 | $932 | $9 |
| Valsartan-Hydrochlorothiazide | 31 | $900 | $29 |
| Furosemide | 110 | $805 | $7 |
| Nitroglycerin | 13 | $773 | $59 |
| Carvedilol | 39 | $685 | $18 |
| Atenolol | 46 | $657 | $14 |
| Lisinopril | 53 | $642 | $12 |
| Diltiazem 24hr Er | 23 | $633 | $28 |
| Simvastatin | 66 | $618 | $9 |
| Nifedical Xl | 11 | $604 | $55 |
| Flecainide Acetate | 13 | $492 | $38 |
| Amiodarone | 24 | $466 | $19 |
| Diltiazem Er | 11 | $381 | $35 |
| Isosorbide Mononitrate | 16 | $349 | $22 |
| Lisinopril-Hydrochlorothiazide | 26 | $230 | $9 |
| Triamterene-Hydrochlorothiazid | 13 | $226 | $17 |
| Losartan | 22 | $224 | $10 |
| Clonidine | 29 | $189 | $7 |
| Digitek | 11 | $162 | $15 |
| Spironolactone | 13 | $154 | $12 |
| Hydrochlorothiazide | 25 | $100 | $4 |
2015: 38 drugs
| Crestor | 61 | $27,811 | $456 |
| Vytorin | 43 | $15,746 | $366 |
| Xarelto | 33 | $15,073 | $457 |
| Zetia | 25 | $9,302 | $372 |
| Metoprolol | 147 | $6,111 | $42 |
| Multaq | 12 | $5,631 | $469 |
| Atorvastatin | 153 | $3,555 | $23 |
| Valsartan | 28 | $3,435 | $123 |
| Potassium Chloride | 73 | $3,148 | $43 |
| Nifedipine Er | 56 | $2,714 | $48 |
| Omega-3 Acid Ethyl Esters | 11 | $2,279 | $207 |
| Isosorbide Mononitrate Er | 76 | $2,269 | $30 |
| Valsartan-Hydrochlorothiazide | 49 | $1,908 | $39 |
| Clopidogrel | 91 | $1,868 | $21 |
| Warfarin | 73 | $1,612 | $22 |
| Nitrostat | 44 | $1,404 | $32 |
| Digoxin | 23 | $1,191 | $52 |
| Amlodipine Besylate | 84 | $934 | $11 |
| Furosemide | 117 | $879 | $8 |
| Digox | 11 | $815 | $74 |
| Metoprolol | 111 | $777 | $7 |
| Simvastatin | 110 | $762 | $7 |
| Carvedilol | 50 | $674 | $13 |
| Atenolol | 48 | $518 | $11 |
| Ramipril | 16 | $488 | $30 |
| Lisinopril | 64 | $476 | $7 |
| Amlodipine Besylate-Benazepril | 14 | $400 | $29 |
| Diltiazem 24hr Er | 19 | $354 | $19 |
| Amiodarone | 18 | $350 | $19 |
| Diltiazem Er | 15 | $324 | $22 |
| Cartia Xt | 13 | $320 | $25 |
| Losartan | 37 | $310 | $8 |
| Digitek | 15 | $302 | $20 |
| Triamterene-Hydrochlorothiazid | 14 | $222 | $16 |
| Hydrochlorothiazide | 30 | $146 | $5 |
| Spironolactone | 19 | $143 | $8 |
| Lisinopril-Hydrochlorothiazide | 13 | $137 | $11 |
| Clonidine | 11 | $117 | $11 |
2014: 40 drugs
| Crestor | 45 | $16,481 | $366 |
| Xarelto | 38 | $12,691 | $334 |
| Vytorin | 48 | $12,091 | $252 |
| Diovan | 19 | $6,310 | $332 |
| Metoprolol | 147 | $5,828 | $40 |
| Zetia | 16 | $5,370 | $336 |
| Potassium Chloride | 88 | $4,622 | $53 |
| Multaq | 11 | $4,265 | $388 |
| Atorvastatin | 158 | $3,611 | $23 |
| Clopidogrel | 81 | $3,259 | $40 |
| Valsartan-Hydrochlorothiazide | 45 | $3,254 | $72 |
| Isosorbide Mononitrate Er | 89 | $2,412 | $27 |
| Nifedipine Er | 51 | $2,347 | $46 |
| Bystolic | 11 | $1,876 | $171 |
| Digoxin | 28 | $1,359 | $49 |
| Warfarin | 75 | $1,289 | $17 |
| Simvastatin | 131 | $1,238 | $9 |
| Amlodipine Besylate | 115 | $1,141 | $10 |
| Digox | 17 | $1,077 | $63 |
| Metoprolol | 108 | $1,013 | $9 |
| Carvedilol | 84 | $1,007 | $12 |
| Amlodipine Besylate-Benazepril | 14 | $948 | $68 |
| Nitrostat | 29 | $802 | $28 |
| Ramipril | 26 | $793 | $30 |
| Furosemide | 114 | $711 | $6 |
| Lisinopril | 90 | $675 | $7 |
| Atenolol | 68 | $611 | $9 |
| Propafenone | 12 | $584 | $49 |
| Amiodarone | 28 | $495 | $18 |
| Diltiazem 24hr Er | 23 | $483 | $21 |
| Diltiazem 24hr Cd | 13 | $483 | $37 |
| Losartan | 44 | $464 | $11 |
| Pantoprazole | 16 | $458 | $29 |
| Triamterene-Hydrochlorothiazid | 20 | $332 | $17 |
| Spironolactone | 25 | $269 | $11 |
| Klor-Con M20 | 11 | $170 | $15 |
| Hydralazine | 12 | $165 | $14 |
| Hydrochlorothiazide | 25 | $149 | $6 |
| Finasteride | 13 | $120 | $9 |
| Clonidine | 13 | $107 | $8 |
2013: 40 drugs
| Crestor | 60 | $17,369 | $289 |
| Diovan | 44 | $11,674 | $265 |
| Vytorin | 50 | $11,176 | $224 |
| Zetia | 34 | $10,308 | $303 |
| Metoprolol | 141 | $6,004 | $43 |
| Clopidogrel | 65 | $5,673 | $87 |
| Valsartan-Hydrochlorothiazide | 47 | $5,399 | $115 |
| Atorvastatin | 123 | $5,221 | $42 |
| Lovaza | 14 | $4,727 | $338 |
| Multaq | 13 | $4,661 | $359 |
| Xarelto | 17 | $4,425 | $260 |
| Potassium Chloride | 86 | $3,309 | $38 |
| Nifedipine Er | 54 | $2,345 | $43 |
| Isosorbide Mononitrate Er | 67 | $2,195 | $33 |
| Amlodipine Besylate | 103 | $1,779 | $17 |
| Simvastatin | 132 | $1,672 | $13 |
| Amlodipine Besylate-Benazepril | 17 | $1,428 | $84 |
| Propafenone | 17 | $1,306 | $77 |
| Carvedilol | 89 | $1,293 | $15 |
| Warfarin | 85 | $1,272 | $15 |
| Metoprolol | 86 | $1,231 | $14 |
| Diltiazem 24hr Cd | 31 | $1,223 | $39 |
| Klor-Con 10 | 31 | $1,082 | $35 |
| Losartan | 31 | $971 | $31 |
| Furosemide | 145 | $949 | $7 |
| Ramipril | 20 | $881 | $44 |
| Lisinopril | 83 | $711 | $9 |
| Nitrostat | 35 | $624 | $18 |
| Nifedical Xl | 13 | $598 | $46 |
| Diltiazem 24hr Er | 15 | $578 | $39 |
| Atenolol | 82 | $565 | $7 |
| Digox | 42 | $527 | $13 |
| Amiodarone | 24 | $437 | $18 |
| Pantoprazole | 19 | $422 | $22 |
| Finasteride | 21 | $358 | $17 |
| Spironolactone | 18 | $236 | $13 |
| Digoxin | 12 | $233 | $19 |
| Doxazosin Mesylate | 11 | $157 | $14 |
| Hydrochlorothiazide | 19 | $129 | $7 |
| Isosorbide Mononitrate | 13 | $84 | $6 |
Money from drug and device companies
$5,742 in 2025
| 2025 | 9 | 20 | $4,000 | $5,742 |
| 2024 | 6 | 36 | $38,200 | $79,170 |
| 2023 | 6 | 13 | None | $577 |
| 2022 | 10 | 27 | $6,400 | $9,619 |
| 2021 | 8 | 20 | $2,069,007 | $2,112,376 |
| 2020 | 4 | 4 | None | $227 |
| 2019 | 6 | 14 | None | $963 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
HeartFlow, Inc.
$8,405,033
Held by this doctor · 2025, 2024, 2023, 2022, 2021, 2020, 2019 · Common Stock, Series A Preferred, Common Shares
Alydia Health
$1,280,108
Held by this doctor · 2021 · Series A Preferred Stock and Series C Preferred Stock
Published ownership or investment in a drug or device company. This is not proof that care is biased.
A payment is not proof that care is biased.
| Abbott Laboratories | Tendyne | $4,958 | 8 payments
|
| Heartflow | Ffrct | $383 | 2 payments
|
| Medtronic | Aurora Ev-Icd Mri Surescan | $254 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $50 | 2 payments
|
| Pfizer | Eliquis | $27 | 1 payment
|
| Amgen | Repatha | $21 | 1 payment
|
See all 20 published payments
| Medtronic | Meals · 2025-12-12 | Aurora Ev-Icd Mri Surescan | $113 |
| Medtronic | Meals · 2025-10-14 | Aurora Ev-Icd Mri Surescan | $58 |
| Medtronic | Meals · 2025-10-01 | Omniasecure Mri Surescan | $82 |
| Abbott Laboratories | Meals · 2025-09-18 | Navitor | $87 |
| Octapharma USA | Meals · 2025-09-10 | Fibryga | $17 |
| Heartflow | Meals · 2025-08-05 | Ffrct | $40 |
| Cordis US | Meals · 2025-07-14 | Mynx Control Venous | $19 |
| Abbott Laboratories | Meals · 2025-07-09 | Amplatzer Talisman | $113 |
| Heartflow | Meals · 2025-06-26 | Ffrct | $343 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-29 | Jardiance | $31 |
| Amgen | Meals · 2025-03-04 | Repatha | $21 |
| Abbott Laboratories | Royalties · 2025-02-06 | Tendyne | $1,500 |
| Abbott Laboratories | Paid to speak or teach · 2025-02-06 | Tendyne | $1,500 |
| Abbott Laboratories | Paid to speak or teach · 2025-02-06 | Tendyne | $500 |
| Abbott Laboratories | Paid to speak or teach · 2025-02-06 | Tendyne | $500 |
| Abbott Laboratories | Travel · 2025-02-06 | Tendyne | $750 |
| Abbott Laboratories | Travel · 2025-02-06 | Tendyne | $9 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-01-14 | Jardiance | $19 |
| Boston Scientific | Meals · 2025-01-07 | Watchman Flx | $13 |
| Pfizer | Meals · 2025-01-06 | Eliquis | $27 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $79,170
| Abbott Laboratories | Mitraclip | $78,898 | 30 payments
|
| Heartflow | Ffrct | $179 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $31 | 1 payment
|
| Boston Scientific | Watchman Flx | $23 | 1 payment
|
| Pfizer | Eliquis | $20 | 1 payment
|
| Amgen | Repatha | $20 | 1 payment
|
2023: $577
| Abbott Laboratories | Optis | $298 | 4 payments
|
| Amgen | Repatha | $117 | 5 payments
|
| HeartFlow | Ffrct | $94 | 1 payment
|
| Merck Sharp & Dohme | Verquvo | $30 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $19 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $18 | 1 payment
|
2022: $9,619
| HeartFlow | Ffrct | $5,000 | 10 payments
|
| Boston Scientific | General - Therapies | $2,872 | 1 payment
|
| Abbott Laboratories | Freestyle Libre | $1,517 | 6 payments
|
| Amgen | Repatha | $51 | 2 payments
|
| Alnylam Pharmaceuticals | Onpattro | $48 | 2 payments
|
| Novartis Pharmaceuticals | Entresto | $42 | 2 payments
|
| Merck Sharp & Dohme | Verquvo | $24 | 1 payment
|
| Pfizer | Eliquis | $23 | 1 payment
|
| Bardy Diagnostics | Carnation Ambulatory Monitor | $22 | 1 payment
|
| Esperion Therapeutics | Nexletol | $20 | 1 payment
|
2021: $2,112,376
| Alydia Health | Jada System | $2,063,507 | 2 payments
|
| Boston Scientific | General Therapies | $43,218 | 1 payment
|
| HeartFlow | Ffrct | $5,548 | 12 payments
|
| Kiniksa Pharmaceuticals | None | $23 | 1 payment
|
| Alnylam Pharmaceuticals | Onpattro | $22 | 1 payment
|
| Amarin Pharma | Vascepa | $21 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $19 | 1 payment
|
| Amgen | Repatha | $17 | 1 payment
|
2020: $227
| Abbott Laboratories | Mitra Clip System | $130 | 1 payment
|
| HeartFlow | None | $57 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $22 | 1 payment
|
| Kowa Pharmaceuticals America | Livalo | $18 | 1 payment
|
2019: $963
| Abbott Laboratories | Mitra Clip System | $780 | 8 payments
|
| Medtronic Vascular | Corevalve Evolut | $66 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $35 | 2 payments
|
| Amgen | Corlanor | $32 | 1 payment
|
| Pfizer | Eliquis | $27 | 1 payment
|
| HeartFlow | None | $22 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 81.2 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1992710453
- Licence
- CA G57372California G57372: Current · expires 2028-01-31
- Trained
- Harvard Medical School, 1984
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA GR0098530
- Taxonomy
- Federal specialty code 207RI0011X (207RI0011X)
- Mailing address
- 2490 Hospital Dr Ste 311, Mountain View, CA, 94040
- NPI first listed
- 2006-07-30
- NPI last updated
- 2011-08-22
This is when the NPI record was last certified, not a medical board exam.